#Keytruda-Biosimilar
ARGENTINA | Argentine lab ELEA develops a biosimilar to Merck’s cancer drug Keytruda, forcing the US giant to slash prices.

(Perfil)
November 6, 2026 at 6:13 PM
Samsung Bioepis aBLA for Keytruda® (pembrolizumab) Biosimilar SB27 Accepted by FDA
Samsung Bioepis aBLA for Keytruda® (pembrolizumab) Biosimilar SB27 Accepted by FDA
On October 30, 2026, Samsung Bioepis announced the FDA acceptance of an aBLA for SB27, a proposed biosimilar of Merck’s Keytruda®...
www.jdsupra.com
November 5, 2026 at 6:34 PM
Samsung Bioepis aBLA for Keytruda® (pembrolizumab) Biosimilar SB27 Accepted by FDA
Samsung Bioepis aBLA for Keytruda® (pembrolizumab) Biosimilar SB27 Accepted by FDA
On October 30, 2026, Samsung Bioepis announced the FDA acceptance of an aBLA for SB27, a proposed biosimilar of Merck’s Keytruda®...
www.jdsupra.com
November 5, 2026 at 6:34 PM
Samsung Bioepis aBLA for Keytruda® (pembrolizumab) Biosimilar SB27 Accepted by FDA
Samsung Bioepis aBLA for Keytruda® (pembrolizumab) Biosimilar SB27 Accepted by FDA
On October 30, 2026, Samsung Bioepis announced the FDA acceptance of an aBLA for SB27, a proposed biosimilar of Merck’s Keytruda®...
www.jdsupra.com
November 5, 2026 at 6:34 PM
→ What they did
The FDA approved the first publicly announced application for a Keytruda biosimilar (FYB206), which could receive approval as early as the third quarter of 2027.
November 2, 2026 at 6:00 PM
17 Approvals for China and India vs. Zero for South Korea: K-Biotech Falls Behind in Biosimilar Race, Prepares Counterattack With Keytruda

https://www.byteseu.com/2490194/

Chinese and Indian companies won a string of biosimilar (copycat biologic drug) approvals in the U.S. and European Union …
17 Approvals for China and India vs. Zero for South Korea: K-Biotech Falls Behind in Biosimilar Race, Prepares Counterattack With Keytruda - Bytes Europe
Chinese and Indian companies won a string of biosimilar (copycat biologic drug) approvals in the U.S. and European Union this year, while South Korean
www.byteseu.com
November 1, 2026 at 1:39 PM
💉 #pharma

🇺🇸 #$MRK Merck raised 2026 non-GAAP EPS outlook to $2.77 to $2.82 from $2.66 to $2.76, including a new $0.12 charge, and its sales floor to $66.8bn.

Q3 sales $18.1bn, +5%, helped by about $0.55bn of purchase timing. #Keytruda $8.6bn, +6%; Qlex $830m.

midgardfinance.com/companies/MRK/
October 29, 2026 at 1:00 PM
Formycon and Zydus File First Publicly Disclosed Keytruda® aBLA Along with PGR
Formycon and Zydus File First Publicly Disclosed Keytruda® aBLA Along with PGR
On October 13, 2026, Formycon and Zydus announced the FDA accepted for review their aBLA for FYB206 (pembrolizumab), a proposed biosimilar of...
www.jdsupra.com
October 27, 2026 at 4:59 PM
Formycon and Zydus File First Publicly Disclosed Keytruda® aBLA Along with PGR
Formycon and Zydus File First Publicly Disclosed Keytruda® aBLA Along with PGR
On October 13, 2026, Formycon and Zydus announced the FDA accepted for review their aBLA for FYB206 (pembrolizumab), a proposed biosimilar of...
www.jdsupra.com
October 27, 2026 at 4:59 PM
Formycon and Zydus File First Publicly Disclosed Keytruda® aBLA Along with PGR
Formycon and Zydus File First Publicly Disclosed Keytruda® aBLA Along with PGR
On October 13, 2026, Formycon and Zydus announced the FDA accepted for review their aBLA for FYB206 (pembrolizumab), a proposed biosimilar of...
www.jdsupra.com
October 27, 2026 at 4:59 PM
Ich habe nach den jüngsten US-News mit #Formycon-CEO Stefan Glombitza ausführlicher über das #Keytruda-Biosimilar #FYB206 gesprochen, das einen Milliardenmarkt erobern soll.

Formycon: „Wir gehören zur Spitzengruppe“ - Interview www.4investors.de/nachrichten/...
Formycon: „Wir gehören zur Spitzengruppe“ - Interview
Formycon-CEO Stefan Glombitza im 4investors.de-Interview über das Keytruda-Biosimilar FYB206, die FDA-Zulassung, Marktchancen und KI in der Entwicklung.
www.4investors.de
October 15, 2026 at 5:56 AM
Wed news: Zealand pens up to $1.2B deal with Generate for AI obesity/metabolic drugs. FDA accepts BLA for first Keytruda biosimilar. Galderma to acquire ZO Skin Health for $1.5B. GSK to cut 1200 jobs in Belgium. —https://bit.ly/3JeBlY5
October 14, 2026 at 4:05 PM
First Keytruda biosimilar accepted for FDA review. The world's best-selling drug ($31.7B in 2025) finally has a challenger in line. Decision expected around Q3 2027. https://thisnewsroom.com/keytruda-biosimilar-fda-review-zydus-formycon/
October 14, 2026 at 1:00 AM
FDA Accepts Review of Zydus Keytruda Biosimilar Application #MarketUpdates Follow Us for more
FDA Accepts Review of Zydus Keytruda Biosimilar Application
The FDA has accepted for review the first publicly announced biosimilar application referencing Merck's Keytruda, developed by Formycon and licensed to
quantli.com
October 13, 2026 at 10:02 PM
Formycon und Zydus: FDA nimmt FYB206 als erstes öffentlich bekannt gegebenes Keytruda®-Biosimilar zur Prüfung an // #Würmtal // marketscreener.com
October 13, 2026 at 2:20 PM
▲ NSE:ZYDUSLIFE Zydus Lifesciences: USFDA accepted BLA for FYB206, a Keytruda biosimilar, with a USFDA decision potentially in Q3 2027; first publicly announced acceptance of a Keytruda biosimilar filing per companies [BULLISH]
October 13, 2026 at 5:00 AM
Zydus Lifesciences Limited — Market Notice

Zydus Lifesciences and Formycon AG jointly announced that the USFDA has accepted for review the Biologics License Application for FYB206, a proposed biosimilar to Keytruda (pembrolizumab), which the companies believe is the first publicly...

🧵 continued ↓
October 13, 2026 at 4:47 AM
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar reut.rs/3Uz8x1Y
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
India's Cipla said on Thursday its U.S. unit entered an ​exclusive partnership with China's Qilu Pharmaceutical ‌to license a biosimilar version of Merck's cancer drug Keytruda for the U.S. ​market.
reut.rs
September 3, 2026 at 7:10 PM
India's Cipla said on Thursday its U.S. unit entered an exclusive partnership with China's Qilu Pharmaceutical to license a biosimilar version of Merck's cancer drug Keytruda for the U.S. market.
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
India's Cipla said on Thursday its U.S. unit entered an ​exclusive partnership with China's Qilu Pharmaceutical ‌to license a biosimilar version of Merck's cancer drug Keytruda for the U.S. ​market.
reut.rs
September 3, 2026 at 3:40 PM
Cipla Teams Up with Qilu Pharmaceutical for Keytruda® Biosimilar in the U.S.#India#Mumbai#Biosimilar#Qilu_Pharmaceutical#Cipla
Cipla Teams Up with Qilu Pharmaceutical for Keytruda® Biosimilar in the U.S.
Cipla and Qilu Pharmaceutical have announced a partnership to license and supply a biosimilar to Keytruda® in the U.S., enhancing cancer treatment access.
third-news.com
September 3, 2026 at 4:30 PM
#Patents on the initial form of a #drug will still expire at the same time, regardless of whether companies obtain patents on later alterations.

For Keytruda, #biosimilar manufacturers will be free to produce & market versions of the intravenous formulation when the initial patents expire.

More ⬇
November 5, 2025 at 8:34 PM